(Tetrazol-5-yl)glycine | CAS#138199-51-6

MedKoo Cat#: 529178 | Name: (Tetrazol-5-yl)glycine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

(Tetrazol-5-yl)glycine is a potent NMDA receptor agonist.

Chemical Structure

(Tetrazol-5-yl)glycine

CAS#138199-51-6

Theoretical Analysis

MedKoo Cat#: 529178

Name: (Tetrazol-5-yl)glycine

CAS#: 138199-51-6

Chemical Formula: C3H5N5O2

Exact Mass: 143.0443

Molecular Weight: 143.11

Elemental Analysis: C, 25.18; H, 3.52; N, 48.94; O, 22.36

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

(Tetrazol-5-yl)glycine

IUPAC/Chemical Name

1H-Tetrazole-5-acetic acid, alpha-amino-, (+-)-

InChi Key

UKBRUIZWQZHXFL-UHFFFAOYSA-N

InChi Code

InChI=1S/C3H5N5O2/c4-1(3(9)10)2-5-7-8-6-2/h1H,4H2,(H,9,10)(H,5,6,7,8)

SMILES Code

O=C(O)C(N)C1=NN=NN1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 143.11 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: An Y, Belevych N, Wang Y, Zhang H, Herschman H, Chen Q, Quan N. Neuronal and nonneuronal COX-2 expression confers neurotoxic and neuroprotective phenotypes in response to excitotoxin challenge. J Neurosci Res. 2014 Apr;92(4):486-95. doi: 10.1002/jnr.23317. Epub 2013 Dec 24. PubMed PMID: 24375716; PubMed Central PMCID: PMC4085774. 2: Lyakhov AS, Voitekhovich SV, Ivashkevich LS, Gaponik PN. A tetrazol-5-yl analogue of glycine, 5-ammoniomethyl-1H-tetrazolide, and its copper(II) complex. Acta Crystallogr C. 2010 Feb;66(Pt 2):m22-5. doi: 10.1107/S0108270109055164. Epub 2010 Jan 8. PubMed PMID: 20124673. 3: Duncan GE, Inada K, Farrington JS, Koller BH. Seizure responses and induction of Fos by the NMDA agonist (tetrazol-5-yl)glycine in a genetic model of NMDA receptor hypofunction. Brain Res. 2008 Jul 24;1221:41-8. doi: 10.1016/j.brainres.2008.05.001. Epub 2008 May 8. PubMed PMID: 18550035; PubMed Central PMCID: PMC2527124. 4: Inada K, Farrington JS, Moy SS, Koller BH, Duncan GE. Assessment of NMDA receptor activation in vivo by Fos induction after challenge with the direct NMDA agonist (tetrazol-5-yl)glycine: effects of clozapine and haloperidol. J Neural Transm (Vienna). 2007 Jul;114(7):899-908. Epub 2007 Feb 22. PubMed PMID: 17318306. 5: Rae C, Moussa Cel-H, Griffin JL, Parekh SB, Bubb WA, Hunt NH, Balcar VJ. A metabolomic approach to ionotropic glutamate receptor subtype function: a nuclear magnetic resonance in vitro investigation. J Cereb Blood Flow Metab. 2006 Aug;26(8):1005-17. Epub 2005 Dec 14. PubMed PMID: 16395280. 6: Nanitsos EK, Acosta GB, Saihara Y, Stanton D, Liao LP, Shin JW, Rae C, Balcar VJ. Effects of glutamate transport substrates and glutamate receptor ligands on the activity of Na-/K(+)-ATPase in brain tissue in vitro. Clin Exp Pharmacol Physiol. 2004 Nov;31(11):762-9. PubMed PMID: 15566390. 7: Costantino G, Maltoni K, Marinozzi M, Camaioni E, Prezeau L, Pin JP, Pellicciari R. Synthesis and biological evaluation of 2-(3'-(1H-tetrazol-5-yl) bicyclo[1.1.1]pent-1-yl)glycine (S-TBPG), a novel mGlu1 receptor antagonist. Bioorg Med Chem. 2001 Feb;9(2):221-7. PubMed PMID: 11249114. 8: Shave E, Pliss L, Lawrance ML, FitzGibbon T, Stastny F, Balcar VJ. Regional distribution and pharmacological characteristics of [3H]N-acetyl-aspartyl-glutamate (NAAG) binding sites in rat brain. Neurochem Int. 2001 Jan;38(1):53-62. PubMed PMID: 10913688. 9: Lembeck F, Sieler D. In vivo effects of the NMDA receptor agonist tetrazolyl-glycine related to the function of small-diameter primary afferents. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jul;360(1):38-41. PubMed PMID: 10463332. 10: Ong WY, Motin LG, Hansen MA, Dias LS, Ayrout C, Bennett MR, Balcar VJ. P2 purinoceptor blocker suramin antagonises NMDA receptors and protects against excitatory behaviour caused by NMDA receptor agonist (RS)-(tetrazol-5-yl)-glycine in rats. J Neurosci Res. 1997 Sep 1;49(5):627-38. PubMed PMID: 9302084. 11: Jardon BL, Bonaventure N. Involvement of NMDA in a plasticity phenomenon observed in the adult frog monocular optokinetic nystagmus. Vision Res. 1997 Jun;37(11):1511-24. PubMed PMID: 9205712. 12: Bains JS, Ferguson AV. Nitric oxide regulates NMDA-driven GABAergic inputs to type I neurones of the rat paraventricular nucleus. J Physiol. 1997 Mar 15;499 ( Pt 3):733-46. PubMed PMID: 9130169; PubMed Central PMCID: PMC1159291. 13: Jones TW, Spuhler-Phillips K, Wilson W, Leslie SW. D, L-(tetrazol-5-yl)glycine stimulation of NMDA receptors in neonatal dissociated neurons: inhibition by ethanol. Alcohol. 1996 Mar-Apr;13(2):181-5. PubMed PMID: 8814654. 14: Arnt J, Sánchez C, Lenz SM, Madsen U, Krogsgaard-Larsen P. Differentiation of in vivo effects of AMPA and NMDA receptor ligands using drug discrimination methods and convulsant/anticonvulsant activity. Eur J Pharmacol. 1995 Oct 24;285(3):289-97. PubMed PMID: 8575516. 15: Moroni F, Galli A, Mannaioni G, Carla V, Cozzi A, Mori F, Marinozzi M, Pellicciari R. NMDA receptor heterogeneity in mammalian tissues: focus on two agonists, (2S,3R,4S) cyclopropylglutamate and the sulfate ester of 4-hydroxy-(S)-pipecolic acid. Naunyn Schmiedebergs Arch Pharmacol. 1995 Apr;351(4):371-6. PubMed PMID: 7543185. 16: Grech DM, Lunn WH, Balster RL. Discriminative stimulus effects of excitatory amino acid agonists in rats. Neuropharmacology. 1995 Jan;34(1):55-62. PubMed PMID: 7623964. 17: Saransaari P, Oja SS. Glycine release from hippocampal slices in developing and ageing mice: modulation by glutamatergic receptors. Mech Ageing Dev. 1994 Oct 20;76(2-3):113-24. PubMed PMID: 7533869. 18: Schoepp DD, Lunn WH, Salhoff CR, McDonald JW. The NMDA receptor agonist DL-(tetrazol-5-yl)glycine is a highly potent excitotoxin. Eur J Pharmacol. 1994 Jan 3;270(1):67-72. PubMed PMID: 8157082. 19: Reynolds IJ. [3H]CGP 39653 binding to the agonist site of the N-methyl-D-aspartate receptor is modulated by Mg2+ and polyamines independently of the arcaine-sensitive polyamine site. J Neurochem. 1994 Jan;62(1):54-62. PubMed PMID: 7903355. 20: Wagner EJ, Moore KE, Lookingland KJ. Sexual differences in N-methyl-D-aspartate receptor-mediated regulation of tuberoinfundibular dopaminergic neurons in the rat. Brain Res. 1993 May 14;611(1):139-46. PubMed PMID: 8518940.